The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters.

	Quarter Ended
	December 31,				September 30,				June 30,				March 31,
(In thousands, except per share amounts)	2016 ⁽¹⁾				2016 ⁽¹⁾				2016 ⁽¹⁾				2016
Revenue	$	425,436			$	392,384			$	386,521			$	345,558
Cost of revenue		239,138				226,225				219,837				193,660
Gross profit		186,298				166,159				166,684				151,898
Selling, general and administrative expenses		115,132				98,778				94,802				84,153
Research and development		47,836				45,142				47,891				47,037
Asset impairment charges		0				0				0				4,650
Amortization of intangible and acquisition-related assets		10,903				5,365				5,417				4,162
Income from operations		12,427				16,874				18,574				11,896
Interest expense		(25,384	)	⁽⁴⁾		(19,367	)			(16,421	)			(6,969	)
Other income (expense), net		621				(6	)			106				366
Equity in net loss of unconsolidated investments		0				0				(4,898	)			(2,603	)
(Loss) income before income taxes		(12,336	)			(2,499	)			(2,639	)			2,690
Income tax benefit (provision)		15,218		⁽³⁾		2,656		⁽³⁾		503		⁽³⁾		(563	)	⁽³⁾
Net income (loss)		2,882				157				(2,136	)			2,127
Less: Net (income) loss attributable to non-controlling interest		(4	)			(151	)			87				(78	)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart		(10,192	)			(10,191	)			(8,153	)			0
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(7,314	)		$	(10,185	)		$	(10,202	)		$	2,049
(Loss) earnings per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(0.04	)		$	(0.06	)		$	(0.05	)		$	0.01

	Quarter Ended
	December 31,				September 30,				June 30,				March 31,
(In thousands, except per share amounts)	2015 ⁽²⁾				2015 ⁽²⁾				2015 ⁽²⁾				2015
Revenue	$	345,647			$	354,476			$	351,718			$	334,552
Cost of revenue		191,844				201,128				208,094				204,762
Gross profit		153,803				153,348				143,624				129,790
Selling, general and administrative expenses		79,354				91,043				86,749				82,029
Research and development		45,995				47,702				44,367				46,727
Asset impairment charges		1,203				22				293				26
Amortization of intangible and acquisition-related assets		4,133				5,712				6,624				6,703
Income (loss) from operations		23,118				8,869				5,591				(5,695	)
Interest expense		(7,403	)			(9,254	)	⁽⁴⁾		(7,483	)			(7,256	)
Other (expense) income, net		(98	)			423				(28	)			1,886
Equity in net (loss) earnings of unconsolidated investments		(797	)			(1,479	)			176				0
Income (loss) before income taxes		14,820				(1,441	)			(1,744	)			(11,065	)
Income tax benefit (provision)		1,557				(3,692	)	⁽³⁾		(1,472	)			981
Net income (loss)		16,377				(5,133	)			(3,216	)			(10,084	)
Less: Net income attributable to non-controlling interest		(50	)			(111	)			(9	)			0
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	16,327			$	(5,244	)		$	(3,225	)		$	(10,084	)
Income (loss) per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	0.09			$	(0.03	)		$	(0.01	)		$	(0.06	)

⁽¹⁾

Results of operations for the quarter include the results of operations of Netsmart since April 19, 2016, the results of HealthMEDX since October 27, 2016, and the results of operations of three third-parties in which we acquired a controlling interest during the quarters ended September 30^th and December 31^st, 2016 from the date of each transaction.

⁽²⁾	Results of operations for the quarter include the results of operations of a third party with a proportionate share allocated to non-controlling interest for the period subsequent to April 17, 2015, which was the date on which we acquired a majority interest in the third party.

⁽³⁾

Income tax benefit (provision) reflects the recognition (release) of a valuation allowance of ($14.3) million, ($3.3) million, $0.9 million, ($0.9) million and $5.9 million for federal credit carryforwards, and foreign and state net operating loss carryforwards in the quarters ended December 31, 2016, September 30, 2016, June 30, 2016, March 31, 2016 and September 30, 2015, respectively.

⁽⁴⁾

Interest expense includes the write-off of $5.2 million deferred debt issuance costs in connection with Netsmart’s amendment of its First Lien Credit Agreement during the quarter ended December 31, 2016 and the write-off of $1.4 million of deferred debt issuance costs in connection with amending the Senior Secured Credit Facility during the quarter ended September 30, 2015.